A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica

J Rheumatol. 1995 Sep;22(9):1660-2.


Objective: The aim of the study was to establish the antiinflammatory equipotency between prednisolone and deflazacort.

Methods: Thirty patients with newly diagnosed polymyalgia rheumatica (PMR) were treated double blind with either prednisolone or deflazacort in a 12-month study. The initial daily dose was 20 mg prednisolone or 24 mg deflazacort.

Results: The clinical control of muscle pain was significantly inferior in the deflazacort group from 6 weeks to 3 months. Otherwise there was no difference in the clinical and biochemical variables. The ratio between antiinflammatory equipotent doses of deflazacort and prednisolone (mg:mg) stabilized at about 1.55 for the daily doses and about 1.40 for the cumulative doses.

Conclusion: In PMR the antiinflammatory equipotency (mg to mg) between deflazacort and prednisolone was close to 1.40 (7:5 mg). Twenty mg prednisolone/day was fully sufficient to suppress symptoms in 94% of the patients.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents / therapeutic use*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Polymyalgia Rheumatica / drug therapy*
  • Prednisolone / therapeutic use*
  • Pregnenediones / therapeutic use*
  • Prospective Studies
  • Time Factors
  • Treatment Outcome


  • Anti-Inflammatory Agents
  • Pregnenediones
  • Prednisolone
  • deflazacort